SCHEMBL4465833

SCHEMBL4465833

CCCCCCCC/C=C\CCCCCCCCC(CC(=O)O)[N+](C)(CCO)C(CCCCCCCC/C=C\CCCCCCCC)CC(=O)O.COS(=O)(=O)[O-]

nearest known ligand 0.39

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 1/20 0.38
FFAR1 O14842 2/20 0.39
FFAR4 Q5NUL3 2/20 0.39
PPARG P37231 4/20 0.38
PPARD Q03181 4/20 0.38
PPARA Q07869 4/20 0.38
TERT O14746 3/20 0.38
PTPN1 P18031 3/20 0.38
TOP1 P11387 3/20 0.38
HSD17B10 Q99714 3/20 0.38
FABP4 P15090 3/20 0.38
F7 P08709 3/20 0.38
F3 P13726 3/20 0.38
MAPT P10636 2/20 0.38
BLM P54132 2/20 0.38
LMNA P02545 2/20 0.38
ALOX15 P16050 2/20 0.38
DUSP3 P51452 2/20 0.38
CYP19A1 P11511 2/20 0.38
PTGS1 P23219 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6675439 0.93 GPR84 (0.40) FFAR1FFAR4MAPTBLMLMNA
SCHEMBL4464049 0.90 PPARG (0.46) FFAR1FFAR4PPARGPPARDPPARA
SCHEMBL7785237 0.89 PSMD14 (0.37) MMP2FAAHSLC6A5FABP3
SCHEMBL6860166 0.82 GPR84 (0.50) FFAR1FFAR4PPARDMAPTBLM
SCHEMBL22371941 0.78 MMP2 (0.42) FFAR1FFAR4PPARGPPARDPPARA
SCHEMBL7768310 0.76 ENPP2 (0.40) MMP2FAAHFABP3
SCHEMBL6673254 0.76 ENPP2 (0.40) MMP2FAAHFABP3
SCHEMBL6740155 0.76 SLC6A5 (0.51) MAPTFAAHSLC6A5ALDH1A1HPGD
SCHEMBL28391418 0.76 PPARG (0.49) FFAR1FFAR4PPARGPPARDPPARA
SCHEMBL1027031 0.75 LPAR3 (0.46) BLMTDP1FAAHKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015036342-A1 METHOD FOR PRODUCING ALKANE CABOXYLIC ACIDS EVONIK INDUSTRIES AG (DE) 2015-03-19 WO claimed
EP-3066065-B1 CATALYTIC HYDROGENATION FOR THE PREPARATION OF AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID AMIDES, DI-, TRI- OR POLYPEPTIDES OR PEPTIDE AMIDES EVONIK DEGUSSA GMBH (DE) 2019-06-19 EP disclosed
US-9878975-B2 Catalytic hydrogenation for producing amines from carboxylic acid amides, carboxylic acid diamides, di-, tri-, or polypeptides, or peptide amides EVONIK DEGUSSA GMBH (DE) 2018-01-30 US disclosed
EP-2917398-B1 COMPOSITION FOR PERMANENTLY HYDROPHILIZING POLYOLEFIN FIBERS AND USE THEREOF SCHILL + SEILACHER GMBH (DE) 2016-12-07 EP disclosed
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides EVONIK DEGUSSA GMBH (DE) 2016-09-22 US disclosed
EP-3066065-A1 CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES Evonik Degussa GmbH (DE) 2016-09-14 EP disclosed
US-20150292144-A1 COMPOSITION FOR PERMANENTLY HYDROPHILIZING POLYOLEFIN FIBERS AND USE THEREOF SCHILL + SEILACHER GMBH (DE) 2015-10-15 US disclosed
WO-2015067450-A1 CATALYTIC HYDROGENATION FOR PRODUCING AMINES FROM CARBOXYLIC ACID AMIDES, CARBOXYLIC ACID DIAMIDES, DI-, TRI-, OR POLYPEPETIDES, OR PEPTIDE AMIDES EVONIK INDUSTRIES AG (DE) 2015-05-14 WO disclosed
EP-2868643-A1 Catalytic hydrogenation for the preparation of amines from carboxylic acid amides, carboxylic acid amides, di-, tri- or polypeptides or peptide amides Evonik Industries AG (DE) 2015-05-06 EP disclosed
WO-2015036342-A1 METHOD FOR PRODUCING ALKANE CABOXYLIC ACIDS EVONIK INDUSTRIES AG (DE) 2015-03-19 WO disclosed
US-7597881-B2 Use of ester quats in compositions as sand-repellent substances GOLDSCHMIDT GMBH (DE) 2009-10-06 US disclosed
US-7297675-B2 Process for the preparation of highly concentrated flowable aqueous solutions of betaines GOLDSCHMIDT GMBH (DE) 2007-11-20 US disclosed
EP-1844753-A2 Utilisation of ester quats in compositions as sand repellent substances Goldschmidt GmbH (DE) 2007-10-17 EP disclosed
US-20070231289-A1 Use of ester quats in compositions as sand-repellent substances GOLDSCHMIDT GMBH (DE) 2007-10-04 US disclosed
EP-1659109-B1 Process for the preparation of highly concentrated, flowable aqueous betaine solutions GOLDSCHMIDT GMBH (DE) 2007-03-21 EP disclosed
US-20070015681-A1 Process for the preparation of highly concentrated flowable aqueous solutions of betaines GOLDSCHMIDT GMBH (DE) 2007-01-18 US disclosed
US-7163916-B2 Process for the preparation of highly concentrated flowable aqueous solutions of betaines GOLDSCHMIDT GMBH (DE) 2007-01-16 US disclosed
US-20060128599-A1 Process for the preparation of highly concentrated flowable aqueous solutions of betaines GOLDSCHMIDT GMBH (DE) 2006-06-15 US disclosed
EP-1466959-A1 Aqueous compositions containing anionic and cationic surfactants for obtaining a yield point Goldschmidt AG (DE) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231289-A1 Use of ester quats in compositions as sand-repellent substances CUTA, DLAT, CRAT CHRM1 580/4885FFAR1 333/4885FFAR4 666/4885
US-20160272571-A1 Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides DAO, DDC, HDGF CHRM1 3589/4885FFAR1 3111/4885FFAR4 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.